With a p/s equivalent to that of the 2017 post-SOX CRL but with revenues exceeding both 2018 & 2019 combined, a growth trend that will continue due to the new drug commercialization, it is clearly less a reflection of the business development of Elite and more the ungrounded expectations of the unknowing. Real investors invest in businesses that grow, as is Elite. The story of Elite's success is only now being written. Looking in the rearview mirror as a means to navigate the path ahead is an unsuccessful tactic in driving as it is in business. Strategy development is not about the past. Or is that not clear?
Market Data 
Markets 
AI
